Broadcom has a massive opportunity ahead with custom AI chips. UiPath has huge potential upside as its revenue starts to accelerate.
Source: https://www.fool.com/investing/2025/12/11/2-artificial-intel…
The only drug named in Trump’s executive order is ibogaine, a psychedelic commonly used to treat depression, anxiety and PTSD among veterans. The drug, a Schedule I substance banned in the U.S., has been backed by Republicans in Texas in recent years who argue in favor of ibogaine’s success with veterans.
As of Dec. 11, 2025, two stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Palantir Technologies (NASDAQ:PLTR | PLTR Price Prediction) shares are bucking the broader tech rally today, declining 5% to $143.
